Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone acetate

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.12
Views: 4779
Rating:

Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi

Professor Chris Parker from the Royal Marsden Hospital, UK, talks to ecancer TV with Professor Charles Ryan from the Helen Diller Family Comprehensive Cancer Centre, University of California, San Francisco, USA, and Professor Karim Fizazi, from the Institut Gustave-Roussy, France.

 

Professor Ryan outlines the latest data from the Cougar 302 study with abiraterone acetate versus placebo in patients who had not yet received chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC).  He explains the latest results that radiographic progression-free survival (rPFS) is positively associated with overall survival. 

He explains how these data were determined, and reports on the strength of the correlation coefficient with survival.  Both experts give their views on rPFS as a potential future surrogate outcome measure for survival, and discuss the need for an additional end-point, such as pain.

This leads to a discussion about the impact of abiraterone acetate on patient-reported pain and functional status in the Cougar 302 study.

 

Professor Ryan shares data on the frequency of bone scan flare after abiraterone acetate is commenced following results of bone scans performed at 8 and 16 weeks in the Cougar 302 study, and the experts share their views on performing imaging with abiraterone acetate treatment in clinical practice.  Also, their views on when patients should be switched to chemotherapy.

 

Moving on, Professor Fizazi talks about the results from the GETUG-AFU 15/0403 study - presented for the first time during the meeting - which compared androgen deprivation therapy (ADT) with or without docetaxel in hormone-sensitive metastatic prostate cancer (HSMPC) in almost 400 patients.  He explains the results, including the data for PFS (both image-based and PSA-based), and gives his views on the value of these findings to clinical practice.  The experts put these results into context with the upcoming STAMPEDE study.

 

Finally, Professor Ryan gives his views on abstract presented that showed a negative effect of corticosteroid use on survival in the AFFIRM trial vs. non-corticosteroid patients, and cautions on what these data might mean to everyday clinical practice.

 

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation